Correction: MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1 (Oncogene, (2016), 35, 48, (6189-6202), 10.1038/onc.2016.151)

L. Venturutti, R. I.Cordo Russo, M. A. Rivas, M. F. Mercogliano, F. Izzo, R. H. Oakley, M. G. Pereyra, M. De Martino, C. J. Proietti, P. Yankilevich, J. C. Roa, P. Guzmán, E. Cortese, D. H. Allemand, T. H. Huang, E. H. Charreau, J. A. Cidlowski, R. Schillaci, P. V. Elizalde

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Correction: MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1 (Oncogene, (2016), 35, 48, (6189-6202), 10.1038/onc.2016.151)'. Together they form a unique fingerprint.

Immunology and Microbiology

Veterinary Science and Veterinary Medicine